Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed unresectable AJCC stage III or stage IV melanoma~* Patients must have metastatic melanoma with a resectable metastatic lesion(s) of sufficient size (≥ 2-3 cm in total) and must be willing to undergo such a resection for experimental purposes.~* Patients should have received maximum one line of systemic therapy (except for ipilimumab) for unresectable or metastatic melanoma.\[~* Patients must be ≥ 18 years and ≤ 75 years of age and must have measurable disease by CT or MRI per RECIST 1.1 criteria (in addition to the resected lesion).~* Patients must have a clinical performance status of ECOG 0 or 1.~* Patients of both genders must be willing to practice a highly effective method of birth control during treatment and for four months after receiving the preparative regimen.~* Patients must be able to understand and sign the Informed Consent document.~Exclusion Criteria:~* Life expectancy of less than three months.~* Patients with metastatic ocular/ mucosal or other non-cutaneous melanoma.~* Adjuvant treatment with ipilimumab within 6 months prior to randomization.~* Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to randomization.~* Patients who have a more than two CNS metastases.~* Patients who have any CNS lesion that is symptomatic, greater than 1 cm in diameter or show significant surrounding edema on MRI scan will not be eligible until they have been treated and demonstrated no clinical or radiologic CNS progression for at least 2 months.~* All patients' toxicities due to prior non-systemic treatment must have recovered to a grade 1 or less. Patients may have undergone minor surgical procedures or focal palliative radiotherapy (to non-target lesions) within the past 4 weeks, as long as all toxicities have recovered to grade 1 or less.~* Women who are pregnant or breastfeeding, because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.~* Any active systemic infections, coagulation disorders or other active major medical illnesses.~* Any autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: ACTIVE_COMPARATOR): 4 cycles of ipilimumab treatment, the standard treatment
- TIL treatment (Type: EXPERIMENTAL): non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2

Based on this trial design, predict the completion outcome and termination type (if applicable).